Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Multiple Cancer Types

This open-label, phase Ib / II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Miscellaneous, Phase I
I/II
Das, Satya
NCT04579757
VICCPHI20125